UBS Downgrades Impax Laboratories To Sell

Analysts at UBS downgraded

from Neutral to Sell. Impax Laboratories shares have gained 99.84 percent over the past 52 weeks, while the S&P 500 index has gained 12.45 percent in the same period. Impax Laboratories' shares declined 3.04 percent to $49.70 in pre-market trading.